Skip to main content
Tony Ho, MD, Neurology, Cambridge, MA

TonyWeishiuHoMD

Neurology • Cambridge, MA

EVP Head of Research and Development. Crispr Therapeutics

Join to view full profile

Dr. Ho is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Ho's full profile

Already have an account?

  • Office

    610 Main St.
    Cambridge, MA 02139
    Phone+1 267-328-7154

Summary

  • Tony is an Oncology Vice President at Astrazeneca, currently leading the Medi-4736 (anti-PD-L1) program after he led the development and approval of Lynparza. Prior to that, Tony successfully repositioned a failed schizophrenia compound in PCOS and won the 2013 Astrazeneca Patent of the Year Award. Tony most recently co-authored two oncology review articles on oncology drug development and the use of intermediate endpoint. Prior to joining AstraZeneca, Tony was the head of Neurology and Ophthalmology at Merck and led several Phase III programs including CGRP receptor antagonist for migraine, A2a receptor antagonist for Parkinson's disease, prostaglandin for glaucoma, and several early programs in neuropathic pain, stroke, Alzheimer’s disease, and alcohol abuse. He has pioneered several novel pain trial designs and has also devised several strategies in decreasing placebo rate. He successfully filed and launched Zioptan four years earlier than initially planned and obtained Maxalt pediatric indication. The FDA praised the pediatric study design in a 2013 JAMA Pediatric review. Prior to joining Merck, Tony was the Co-Founder and Chief Scientific Officer of Neuronyx, a start-up company that developed stem cells for heart failure and immune-oncology. Tony completed his B.S. in Electrical Engineering at the University of California, Los Angeles, and received his M.D. from the Johns Hopkins University. He was Assistant Professor at Johns Hopkins Hospital specialized in neuropathy and neuromuscular diseases. Tony describing and elucidating the pathogenesis of a new disease called "acute motor axonal neuropathy (AMAN)". He has published widely in several fields with over 70 papers. He is currently Adjunct Associate Professor of Neurology at University of Pennsylvania and Assistant Professor (Part-time) of Neurology at Johns Hopkins University.

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Neurology, 1993 - 1996
  • Massachusetts General Hospital
    Massachusetts General HospitalResidency, Internal Medicine, 1991 - 1992
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 1991
  • University of California, Los Angeles
    University of California, Los AngelesB.S., Electrical Engineering, Summa cum Laude, 1984 - 1987

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 2000 - 2024

Awards, Honors, & Recognition

  • Innovative Medicine & Early Development Science Award: Best Patent 2014
  • Global Medicines Development Team of the Year 2013
  • MRL Key R&D Late-Stage Supplemental Award 2011
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maint...  
    Dougherty BA, Lai Z, Hodgson DR, Orr MCM, Hawryluk M, Sun J, Yelensky R, Spencer SK, Robertson JD, Ho TW, Fielding A, Ledermann JA, Barrett JC, Oncotarget, 1/1/2017
  • Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization  
    Lheureux S, Lai Z, Dougherty BA, Runswick S, Hodgson DR, Timms KM, Lanchbury JS, Kaye S, Gourley C, Bowtell D, Kohn EC, Scott C, Matulonis U, Panzarella T, Karakasis K..., Clin Cancer Res, 1/1/2017
  • Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety  
    Matulonis UA, Penson RT, Domchek SM, Kaufman B, Shapira-Frommer R, Audeh MW, Kaye S, Molife LR, Gelmon KA, Robertson JD, Mann H, Ho TW, Coleman RL, Ann Oncol, 1/1/2016
  • Join now to see all

Books/Book Chapters

  • Campylobacter 
    Chapter: The association of Campylobacter jejuni with Guillain-Barr� Syndrome 
    Nachamkin, I., Allos, B.M., Ho, T.W.Editors: Nachamkin, I., Blaser, M.J..ASM Press, Washington, DCEdition 2nd,1999
  • Immunotherapy in Neuroimmunologic Diseases 
    Chapter: Treatment of the Guillain-Barr� syndrome 
    Page 129 - 135Griffin JW and Ho TWEditors: Zhang J, Hafler D, Hohlfeld R and Miller A.Martin Dunitz1998
  • Comprehensive Neurology 
    Chapter: Diseases of the Peripheral Nervous System 
    Page 707 - 730Griffin JW and Ho TWEditors: Rosenberg RN and Pleasure DE.John Wiley & Sons, Inc.1998
  • Join now to see all

Lectures

  • AZD 6738 ATR inhibitor 
    Santa Monica, CA - 1/18/2015
  • Tremelimumab 
    Santa Monica, CA - 1/18/2015
  • Challenges of Development of Novel Therapeutics in Ovarian Cancer 
    1/7/2015
  • Join now to see all

Other

  • Acute Motor and Sensory Axonal Neuropathy (AMSAN) 
    Ho TW, Encyclopedia of the Neurological Sciences
    1/1/2002

Grant Support

  • Mechanism Of Injury In The Guillain Barre SyndromeNational Institute Of Neurological Disorders And Stroke1997–1999
  • Studies Of The Chinese Paralytic SyndromeNational Institute Of Neurological Disorders And Stroke1992

Dr. Tony Ho, Dr. Tony Ho, MD, Dr. T Ho, Dr. Tony Weishiu Ho